32 related articles for article (PubMed ID: 38554297)
1. Considerable interlaboratory variation in PD-L1 positivity for head and neck squamous cell carcinoma in the Netherlands- A nationwide evaluation study.
Hempenius MA; Koomen BM; Deckers IAG; Oosting SF; Willems SM; van der Vegt B
Histopathology; 2024 Jul; 85(1):133-142. PubMed ID: 38606992
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of Programmed Cell Death Ligand 1 (PDL1) expression by combined positive score using 22C3 clone in head and neck squamous cell carcinomas, its correlation with clinicopathological features and outcome.
Gangadhar P; Ilanthodi S; Shetty R; Shenoy KK; Philipose TR
J Oral Maxillofac Pathol; 2024; 28(1):29-36. PubMed ID: 38800420
[TBL] [Abstract][Full Text] [Related]
3. The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
Heineman TE; Widman A; Kuan EC; St John M
Laryngoscope Investig Otolaryngol; 2017 Jun; 2(3):99-103. PubMed ID: 28894827
[TBL] [Abstract][Full Text] [Related]
4. PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC.
Kaufman B; Taha T; Abramov O; Zohar Y; Mhameed K; Cohen O; Porgador A; Elkabets M; Billan S
NPJ Precis Oncol; 2024 Jun; 8(1):126. PubMed ID: 38830971
[TBL] [Abstract][Full Text] [Related]
5. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
6. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center.
Kilaru S; Panda SS; Moharana L; Mohapatra D; Mohapatra SSG; Panda A; Kolluri S; Devaraj S; Biswas G
J Egypt Natl Canc Inst; 2024 Jan; 36(1):3. PubMed ID: 38285225
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma.
Wusiman D; Guo L; Huang Z; Li Z; Liu S; Ying J; Li W; An C
Pathol Res Pract; 2022 Aug; 236():153934. PubMed ID: 35691098
[TBL] [Abstract][Full Text] [Related]
9. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre.
Kilaru S; Panda SS; Moharana L; Mohapatra D; Mohapatra SSG; Panda A; Kolluri S; Devaraj S; Kabi A; Das B; Biswas G
J Cancer Res Ther; 2024 Jan; 20(1):46-51. PubMed ID: 38554297
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
Paolino G; Pantanowitz L; Barresi V; Pagni F; Munari E; Moretta L; Brunelli M; Bariani E; Vigliar E; Pisapia P; Malapelle U; Troncone G; Girolami I; Eccher A
Pathol Res Pract; 2021 Oct; 226():153605. PubMed ID: 34530257
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Evrard D; Hourseau M; Couvelard A; Paradis V; Gauthier H; Raymond E; Halimi C; Barry B; Faivre S
Oncoimmunology; 2020 Nov; 9(1):1844403. PubMed ID: 33299655
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
